News Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012
DateTitle 
08/07/15Heron Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate ProgressPrinter Friendly Version
07/23/15Heron Therapeutics Initiates Second Phase 2 Clinical Trial of HTX-011 for the Treatment of Post-Operative PainPrinter Friendly Version
07/20/15Heron Therapeutics Resubmits SUSTOL® New Drug Application to FDAPrinter Friendly Version
06/16/15Heron Therapeutics Initiates Phase 2 Clinical Trial of HTX-011 for the Treatment of Post-Operative PainPrinter Friendly Version
06/15/15Heron Therapeutics, Inc. Closes Underwritten Offering of Common StockPrinter Friendly Version
06/10/15Heron Therapeutics, Inc. Announces Pricing of Underwritten Offering of Common StockPrinter Friendly Version
06/09/15Heron Therapeutics, Inc. Announces Proposed Underwritten Offering of Common StockPrinter Friendly Version
05/28/15Heron Therapeutics Announces Positive Results from Phase 3 MAGIC Study of SUSTOL® Printer Friendly Version
05/26/15Heron Therapeutics to Present at Investor Conferences in June 2015Printer Friendly Version
05/14/15Heron Therapeutics Announces Positive Outcome from Meeting with FDA for HTX-019Printer Friendly Version
05/08/15Heron Therapeutics Announces First Quarter 2015 Financial Results and Corporate ProgressPrinter Friendly Version
04/27/15Heron Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care ConferencePrinter Friendly Version
04/02/15Heron Therapeutics Reaches Target Patient Enrollment in MAGIC Phase 3 Study of SUSTOL® Printer Friendly Version
03/19/15Heron Therapeutics Reports Positive Results From Phase 1 Study of HTX-011Printer Friendly Version
03/13/15Heron Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate ProgressPrinter Friendly Version
02/23/15Heron Therapeutics to Present at Upcoming Healthcare ConferencesPrinter Friendly Version
02/11/15Heron Therapeutics Initiates Phase 1 Clinical Study of HTX-011 for the Treatment of Post-Operative PainPrinter Friendly Version
02/03/15Heron Therapeutics to Present at the Leerink Partners 2015 Global Healthcare ConferencePrinter Friendly Version
12/02/14Heron Therapeutics to Present at the Oppenheimer 25th Annual Healthcare ConferencePrinter Friendly Version
11/06/14Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINVPrinter Friendly Version
11/06/14Heron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate HighlightsPrinter Friendly Version
08/25/14Heron Therapeutics Appoints Esmé C. Smith as Vice President, General Counsel and SecretaryPrinter Friendly Version
08/04/14Heron Therapeutics Announces Second Quarter and Year-to-Date 2014 Financial ResultsPrinter Friendly Version
06/30/14Heron Therapeutics, Inc. Closes Underwritten Offering of Common StockPrinter Friendly Version
06/25/14Heron Therapeutics, Inc. Announces Pricing of Underwritten Offering of Common StockPrinter Friendly Version
06/24/14Heron Therapeutics, Inc. Announces Proposed Underwritten Offering of Common StockPrinter Friendly Version
06/20/14Heron Therapeutics Set to Join Russell 3000 IndexPrinter Friendly Version
06/12/14Heron Therapeutics to Present at the 9th Annual JMP Securities Healthcare ConferencePrinter Friendly Version
06/02/14Heron Therapeutics Provides Update on SUSTOL™ ProgramPrinter Friendly Version
05/20/14Heron Therapeutics to Present at the Jefferies 2014 Global Health Care ConferencePrinter Friendly Version
05/19/14Heron Therapeutics Announces Data on SUSTOL™ Program to be Presented at 2014 ASCO Annual MeetingPrinter Friendly Version
05/14/14Heron Therapeutics Reports Positive Results for Post-Surgical Pain ProgramPrinter Friendly Version
05/08/14Heron Therapeutics Announces First Quarter 2014 Financial ResultsPrinter Friendly Version
05/01/14Heron Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care ConferencePrinter Friendly Version
03/31/14Heron Therapeutics Initiates Phase 3 Label Expansion Study of SUSTOL™Printer Friendly Version
03/05/14Heron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate ProgressPrinter Friendly Version
01/27/14Heron Therapeutics Provides Update on Sustol ResubmissionPrinter Friendly Version
01/23/14Heron Therapeutics Announces Relisting on NASDAQ Printer Friendly Version
01/13/14A.P. Pharma Announces Appointment of New Directors and Effective Date of Name Change and Reverse Stock SplitPrinter Friendly Version
11/25/13A.P. Pharma Closes Underwritten Offering of Common StockPrinter Friendly Version
11/20/13A.P. Pharma Announces Pricing of Underwritten Offering of Common StockPrinter Friendly Version
11/19/13A.P. Pharma Announces Proposed Underwritten Offering of Common StockPrinter Friendly Version
11/12/13A.P. Pharma Announces Pipeline ExpansionPrinter Friendly Version
11/12/13A.P. Pharma Announces Third Quarter 2013 Financial Results and Highlights Recent Corporate ProgressPrinter Friendly Version
11/04/13A.P. Pharma Makes Key Management AppointmentsPrinter Friendly Version
08/08/13A.P. Pharma, Inc. Announces Planned Name Change to “Heron Therapeutics, Inc.” and Application to List on NASDAQ Capital MarketPrinter Friendly Version
08/08/13A.P. Pharma Announces Second Quarter 2013 Financial Results and Highlights Recent Corporate ProgressPrinter Friendly Version
07/08/13A.P. Pharma to Present at 8th Annual JMP Securities Healthcare ConferencePrinter Friendly Version
05/10/13A.P. Pharma Announces First Quarter 2013 Financial Results and Highlights Recent Corporate ProgressPrinter Friendly Version
05/02/13A.P. Pharma Appoints New Management TeamPrinter Friendly Version
03/28/13A.P. Pharma Receives FDA Complete Response Letter for APF530Printer Friendly Version
03/01/13A.P. Pharma Announces Fourth Quarter and Full Year 2012 Financial Results and Highlights Recent Corporate ProgressPrinter Friendly Version
02/28/13A.P. Pharma Appoints Jesse Hollingsworth as Vice President of SalesPrinter Friendly Version
12/17/12A.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval of Lead Product Candidate, APF530Printer Friendly Version
12/13/12A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical OfficerPrinter Friendly Version
11/05/12A.P. Pharma Announces Third Quarter 2012 Financial Results and Highlights Recent Corporate ProgressPrinter Friendly Version
10/18/12A.P. Pharma Appoints Robert Rosen as Senior Vice President and Chief Commercial OfficerPrinter Friendly Version
10/16/12A.P. Pharma Announces PDUFA Action Date for APF530 New Drug Application ResubmissionPrinter Friendly Version
09/28/12A.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and VomitingPrinter Friendly Version
09/10/12A.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President of Business DevelopmentPrinter Friendly Version
08/02/12A.P. Pharma Announces Second Quarter 2012 Financial Results and Highlights Recent Corporate ProgressPrinter Friendly Version
07/31/12A.P. Pharma Appoints Robert Rosen to Its Board of DirectorsPrinter Friendly Version
07/25/12A.P. Pharma to Raise $53.6 Million in Common Stock OfferingPrinter Friendly Version
07/10/12A.P. Pharma Announces the Allowance of Three Patents Covering APF530Printer Friendly Version
06/29/12A.P. Pharma Announces Positive APF530 Patient-Satisfaction Data from Phase 3 Study in Patients with Chemotherapy-Induced Nausea and VomitingPrinter Friendly Version
06/21/12A.P. Pharma Appoints Barry Quart and Stephen Davis to Its Board of DirectorsPrinter Friendly Version
06/20/12A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 StudyPrinter Friendly Version
05/31/12A.P. Pharma Announces Study Finding Continuous Exposure to a 5-HT3 Antagonist Using APF530 Provides Better Emetic ControlPrinter Friendly Version
05/10/12A.P. Pharma Announces First Quarter 2012 Financial Results and Recent Corporate ProgressPrinter Friendly Version
03/26/12APF530 Thorough QT Study Showed No Effect on Cardiac RepolarizationPrinter Friendly Version
03/26/12A.P. Pharma Announces Fourth Quarter and Full Year 2011 Financial Results and Provides Update on APF530Printer Friendly Version
03/26/12A.P. Pharma Appoints Thomas Ottoboni, Ph.D. as Vice President of Pharmaceutical DevelopmentPrinter Friendly Version
01/06/12A.P. Pharma to Present at OneMedForum 2012 Financial ConferencePrinter Friendly Version
11/07/11A.P. Pharma Announces Third Quarter 2011 Financial Results and Recent Corporate ProgressPrinter Friendly Version
08/08/11A.P. Pharma Announces Second Quarter 2011 Financial Results and Reports on Recent Corporate ProgressPrinter Friendly Version
06/29/11A.P. Pharma to Raise $24 Million in Private Placement of Common Stock and WarrantsPrinter Friendly Version
05/16/11A.P. Pharma Announces First Quarter 2011 Financial Results and Recent Corporate ProgressPrinter Friendly Version
04/25/11A.P. Pharma Announces Financing of Up to $4.5 Million and Names CEO and COOPrinter Friendly Version
04/25/11A.P. Pharma Provides Regulatory Update on APF530 NDAPrinter Friendly Version
03/31/11A.P. Pharma Announces Transfer to OTCQBPrinter Friendly Version
03/28/11A.P. Pharma Announces Fourth Quarter and Full Year 2010 Financial Results and Provides Corporate UpdatePrinter Friendly Version
02/09/11A.P. Pharma Provides Update on APF530 Program and NASDAQ ListingPrinter Friendly Version
11/22/10A.P. Pharma Receives Second Letter from NASDAQ Regarding Notice of Non-Compliance; Company to Request HearingPrinter Friendly Version
11/15/10A.P. Pharma Announces Third Quarter 2010 Financial ResultsPrinter Friendly Version
08/16/10A.P. Pharma Announces Second Quarter 2010 Financial ResultsPrinter Friendly Version
05/26/10A.P. Pharma Announces Changes in Management and Hires Leading Consulting Practice to Lead FDA Review ProcessPrinter Friendly Version
05/20/10A.P. Pharma Receives Notice Related to Nasdaq Minimum Closing Bid Price RulePrinter Friendly Version
05/17/10A.P. Pharma Announces First Quarter 2010 Financial ResultsPrinter Friendly Version
03/19/10A.P. Pharma Receives FDA Complete Response Letter for APF530Printer Friendly Version
03/15/10A.P. Pharma Announces Fourth Quarter and Year-End 2009 Financial ResultsPrinter Friendly Version
02/19/10A.P. Pharma Appoints Stephen R. Davis to Its Board of DirectorsPrinter Friendly Version
01/11/10A.P. Pharma Receives $2.5 Million Milestone PaymentPrinter Friendly Version
01/11/10A.P. Pharma Regains Compliance with Nasdaq Minimum Bid Price RulePrinter Friendly Version
11/23/09A.P. Pharma Receives Notice of Compliance with Nasdaq Continued Listing RequirementsPrinter Friendly Version
11/16/09A.P. Pharma Reports Third Quarter 2009 Financial ResultsPrinter Friendly Version
10/28/09A.P. Pharma to Transfer to Nasdaq Capital MarketPrinter Friendly Version
10/20/09A.P. Pharma Announces Private Equity PlacementPrinter Friendly Version
09/21/09A.P. Pharma Receives Notice Related to Nasdaq Minimum Closing Bid Price RulePrinter Friendly Version
09/15/09A.P. Pharma and Merial Enter into Worldwide AgreementPrinter Friendly Version
08/04/09A.P. Pharma Reports Second Quarter 2009 Financial ResultsPrinter Friendly Version
07/20/09A.P. Pharma Receives Nasdaq Notice of Non-Compliance; Company to Request HearingPrinter Friendly Version
07/20/09A.P. Pharma Announces FDA Acceptance of APF530 New Drug Application for Chemotherapy-Induced Nausea and VomitingPrinter Friendly Version
06/03/09A.P. Pharma Receives Extension for Nasdaq Listing CompliancePrinter Friendly Version
06/01/09A.P. Pharma Presents APF530 Phase 3 Data at Annual Meeting of the American Society of Clinical OncologyPrinter Friendly Version
05/29/09A.P. Pharma Announces Additional Restructuring EffortPrinter Friendly Version
05/18/09A.P. Pharma Submits New Drug Application for APF530 in Chemotherapy-Induced Nausea and VomitingPrinter Friendly Version
05/18/09APF530 Phase 3 Data for Chemotherapy-Induced Nausea and Vomiting to be Presented at American Society of Clinical Oncology 2009 Annual MeetingPrinter Friendly Version
05/14/09A.P. Pharma Reports First Quarter 2009 Financial ResultsPrinter Friendly Version
04/07/09A.P. Pharma Receives Nasdaq Stockholder Equity NotificationPrinter Friendly Version
03/31/09A.P. Pharma Announces Fourth Quarter and Year-End 2008 Financial Results and Provides Update on APF530 NDAPrinter Friendly Version
02/25/09A.P. Pharma Appoints John B. Whelan as Chief Financial OfficerPrinter Friendly Version
12/18/08A.P. Pharma Revises Target Date for APF530 NDAPrinter Friendly Version
11/05/08A.P. Pharma Reports Results for the Third Quarter 2008Printer Friendly Version
11/03/08A.P. Pharma to Present at Rodman & Renshaw 10th Annual Healthcare Conference on November 12Printer Friendly Version
10/29/08A.P. Pharma to Hold 2008 Third Quarter Financial Results Conference Call November 5Printer Friendly Version
09/30/08A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINVPrinter Friendly Version
09/29/08A.P. Pharma to Hold APF530 Phase 3 Trial Results Conference Call September 30 at 9:00 a.m. EasternPrinter Friendly Version
08/14/08A.P. Pharma Reports Results for the Second Quarter 2008Printer Friendly Version
07/31/08A.P. Pharma to Hold 2008 Second Quarter Financial Results Conference Call August 14Printer Friendly Version
07/09/08A.P. Pharma Announces Stock Option GrantPrinter Friendly Version
07/07/08A.P. Pharma Appoints Ronald J. Prentki as President, Chief Executive Officer and Member of Its Board of DirectorsPrinter Friendly Version
06/23/08A.P. Pharma Completes Enrollment in Phase 3 Trial of APF530Printer Friendly Version
05/15/08A.P. Pharma Reports Results for the First Quarter 2008Printer Friendly Version
05/12/08A.P. Pharma to Hold 2008 First Quarter Financial Results Conference Call May 15Printer Friendly Version
03/31/08A.P. Pharma Announces Stock Option GrantsPrinter Friendly Version
03/13/08A.P. Pharma Reports Results for the Fourth Quarter and Full Year 2007Printer Friendly Version
03/10/08A.P. Pharma to Hold 2007 Fourth Quarter Financial Results Conference Call March 13Printer Friendly Version
01/16/08A.P. Pharma Announces Stock Option GrantPrinter Friendly Version
01/14/08A.P. Pharma Announces Executive Officer DeparturePrinter Friendly Version
01/02/08Dutton Associates Announces Investment Opinion: A.P. Pharma Rated Strong Speculative Buy in Update Report by Dutton AssociatesPrinter Friendly Version
12/21/07A.P. Pharma Announces Chief Executive Officer Succession PlanPrinter Friendly Version
12/14/07A.P. Pharma Stockholders Approve 2007 Equity Incentive Plan and Amendment to 1997 Employee Stock Purchase PlanPrinter Friendly Version
11/13/07A.P. Pharma Reports Third Quarter Financial ResultsPrinter Friendly Version
11/08/07A.P. Pharma to Hold 2007 Third Quarter Financial Results Conference Call November 13Printer Friendly Version
09/10/07A.P. Pharma to Present at Merriman Curhan Ford's Annual Investor Summit on September 17Printer Friendly Version
08/01/07A.P. Pharma Reports Second Quarter Financial ResultsPrinter Friendly Version
07/25/07A.P. Pharma to Hold 2007 Second Quarter Financial Results Conference Call August 1Printer Friendly Version
06/25/07A.P. Pharma Regains Compliance with NASDAQ Global Market Listing RequirementsPrinter Friendly Version
06/19/07A.P. Pharma Closes $40 Million Common Stock Offering; Underwriters Exercise Full over-Allotment OptionPrinter Friendly Version
06/14/07A.P. Pharma Prices $35 Million Common Stock OfferingPrinter Friendly Version
06/07/07A.P. Pharma Receives $2.5 Million Milestone PaymentPrinter Friendly Version
05/24/07A.P. Pharma Clarifies Effective Date of Reverse Stock SplitPrinter Friendly Version
05/23/07A.P. Pharma Stockholders Approve Reverse Stock SplitPrinter Friendly Version
05/15/07A.P. Pharma Reports Receipt of Notice From NASDAQPrinter Friendly Version
05/08/07A.P. Pharma Reports Results for the First Quarter 2007Printer Friendly Version
05/01/07A.P. Pharma to Hold 2007 First Quarter Financial Results Conference Call May 8Printer Friendly Version
04/05/07A.P. Pharma Files Registration Statement for a Common Stock OfferingPrinter Friendly Version
04/05/07A.P. Pharma's 10-K Report Audit Includes 'Going-Concern' QualificationPrinter Friendly Version
03/07/07A.P. Pharma Reports Results for the Fourth Quarter and Full Year 2006; Reports on Progress of APF530 ProgramPrinter Friendly Version
02/28/07A.P. Pharma to Hold 2006 Fourth Quarter Financial Results Conference Call March 7Printer Friendly Version
01/10/07Dutton Associates Announces Investment Opinion: AP Pharma Strong Speculative Buy In Update By Dutton AssociatesPrinter Friendly Version
12/21/06A.P. Pharma Resets APF530 NDA Filing ExpectationsPrinter Friendly Version
11/20/06A.P. Pharma Names New Vice President of Clinical DevelopmentPrinter Friendly Version
11/07/06A.P. Pharma Reports 2006 Third Quarter ResultsPrinter Friendly Version
10/31/06A.P. Pharma to Hold 2006 Third Quarter Financial Results Conference Call November 7Printer Friendly Version
10/02/06A.P. Pharma Licenses APF530 to RHEI Pharmaceuticals for Development in Greater ChinaPrinter Friendly Version
09/28/06A.P. Pharma Expects Data from APF530 Pivotal Trial in Second Half of 2007Printer Friendly Version
09/12/06A.P. Pharma to Present at Merriman Curhan Ford ''Investor Summit 2006'' on September 18Printer Friendly Version
08/14/06A.P. Pharma Names Arthur Taylor to Board of DirectorsPrinter Friendly Version
08/08/06A.P. Pharma Reports 2006 Second Quarter Results; Phase 3 Clinical Trial for APF530 UnderwayPrinter Friendly Version
07/28/06A.P. Pharma to Hold 2006 Second Quarter Financial Results Conference Call August 8Printer Friendly Version
06/27/06Dutton Associates Announces Investment Opinion: A.P. Pharma Maintained At Strong Speculative Buy Rating By Dutton AssociatesPrinter Friendly Version
05/10/06A.P. Pharma Reports 2006 First Quarter Results; Phase 3 Clinical Trial for APF530 InitiatedPrinter Friendly Version
04/27/06A.P. Pharma Initiates APF530 Phase 3 Clinical Trial; IRB Approval ReceivedPrinter Friendly Version
03/15/06A.P. Pharma Reports 2005 Full Year and Fourth Quarter Results; APF530 Phase 3 Clinical Trial Planning at Advanced Stage, Patient Enrollment Expected to Begin in AprilPrinter Friendly Version
03/09/06A.P. Pharma to Hold 2005 Fourth Quarter Financial Results Conference Call March 15Printer Friendly Version
02/08/06Dutton Associates Announces Investment Opinion: A.P. Pharma Inc. Strong Speculative Buy Rating and $3.00 Price Target Reiterated in Update by Dutton AssociatesPrinter Friendly Version
01/24/06A.P. Pharma Announces Submission of APF530 Pivotal Trial Protocol for FDA Review; Phase 3 Trial to Compare APF530 With PalonosetronPrinter Friendly Version
01/18/06A.P. Pharma Regains Compliance with NASDAQ National Market Listing Requirements; NASDAQ Believes Company in Compliance Based on Royalty Interest SalePrinter Friendly Version
01/18/06A.P. Pharma Completes Financing for up to $30 Million; Sells Royalty Rights to Retin-A Micro and Carac; Transaction is Non-Dilutive to ShareholdersPrinter Friendly Version
11/16/05A.P. Pharma Reports Receipt of Notice from NASDAQPrinter Friendly Version
11/04/05Dutton Associates Announces Investment Opinion: A.P. Pharma Raised to Strong Speculative Buy Rating in Update by Dutton AssociatesPrinter Friendly Version
11/03/05A.P. Pharma to Present at Rodman & Renshaw Techvest 7th Annual Healthcare ConferencePrinter Friendly Version
11/02/05A.P. Pharma Reports Third Quarter Results; Preparations Underway for Pivotal Clinical Trials with APF530Printer Friendly Version
10/26/05A.P. Pharma to Hold 2005 Third Quarter Financial Results Conference Call November 2Printer Friendly Version
10/04/05A.P. Pharma to Hold APF530 Phase 2 Results Conference Call Today at 11:00 a.m. Eastern TimePrinter Friendly Version
09/29/05A.P. Pharma Reports All Clinical Endpoints Achieved in APF530 Phase 2 Trial; Conference Call to Begin at 11:00 A.M. Eastern Time Tuesday, October 4, 2005Printer Friendly Version
08/08/05A.P. Pharma Reports Second Quarter Financial Results; Patient Enrollment for APF530 Phase 2 Trial Successfully CompletedPrinter Friendly Version
07/29/05A.P. Pharma to Hold 2005 Second Quarter Financial Results Conference Call August 8Printer Friendly Version
05/10/05A.P. Pharma Reports 2005 First Quarter Results; Cancer Patients Enrolled in Phase 2 Clinical Program for APF530Printer Friendly Version
05/03/05A.P. Pharma to Hold 2005 First Quarter Financial Results Conference Call May 10Printer Friendly Version
04/28/05A.P. Pharma Initiates APF530 Phase 2 Clinical Trial Program in Cancer PatientsPrinter Friendly Version
04/01/05Dutton & Associates Announces Investment Opinion: A.P. Pharma, Inc. Speculative Buy Rating in Update by Dutton AssociatesPrinter Friendly Version
03/10/05A.P. Pharma Reports 2004 Fourth Quarter and Full Year Results; IND Submitted for APF530; Phase 2 Study Cleared to Begin in 2Q05Printer Friendly Version
03/03/05A.P. Pharma to Hold 2004 Fourth Quarter & Year-End Financial Results Conference Call March 10Printer Friendly Version
11/15/04A.P. Pharma Reports Third Quarter Financial Results; APF530 Phase 1 Study Successfully CompletedPrinter Friendly Version
11/05/04A.P. Pharma to Hold 2004 Third Quarter Financial Results Conference Call November 15Printer Friendly Version
09/17/04A.P. Pharma to Hold Clinical and Business Update Conference Call September 21; Company to Discuss Development Plans for APF112 and APF530Printer Friendly Version
08/12/04A.P. Pharma Reports Second Quarter Financial ResultsPrinter Friendly Version
08/12/04A.P. Pharma Reports Preliminary Clinical Data Results from Studies Using APF112 AND APF530; Conference Call to Begin Today at 12:00 Noon ET/9:00 a.m. PTPrinter Friendly Version
08/12/04A.P. Pharma to Hold Conference Call at 12 Noon Eastern Time Today to Discuss APF112 and APF530 Preliminary Trial Results, Second Quarter FinancialsPrinter Friendly Version
08/06/04A.P. Pharma to Hold 2004 Second Quarter Financial Results Conference Call August 16; Company to Report APF112 and APF530 Preliminary Trial ResultsPrinter Friendly Version
06/24/04A.P. Pharma Completes Common Stock SalePrinter Friendly Version
05/05/04A.P. Pharma Files Shelf Registration StatementPrinter Friendly Version
04/28/04A.P. Pharma Reports First Quarter Results; Human Clinical Trials Underway with Two Product CandidatesPrinter Friendly Version
04/21/04A.P. Pharma to Hold 2004 First Quarter Financial Results Conference Call April 28Printer Friendly Version
04/16/04A.P. Pharma Initiates Phase I Clinical Trial with APF530, a Potential Treatment for Chemotherapy-Induced Nausea and VomitingPrinter Friendly Version
03/12/04A.P. Pharma Reports 2003 Fourth Quarter and Full Year Results; Reports Results of Open-Label APF112 Phase 2 studyPrinter Friendly Version
03/04/04A.P. Pharma to Hold 2003 Fourth Quarter and Full-Year Financial Results Conference Call March 12Printer Friendly Version
02/24/04Study Indicates A.P. Pharma Polymer System Could Advance Clinical Utility of DNA Vaccines Against Cancer and Viral Infections; Data Published in Nature MaterialsPrinter Friendly Version
01/26/04A.P. Pharma Provides APF112 Clinical Development Update; Phase II Data Expected by Mid-YearPrinter Friendly Version
11/07/03A.P. Pharma Reports Third Quarter Results; APF112 Phase II Clinical Trial Initiated; Royalty Income Increases 23% Over Q3 2002Printer Friendly Version
10/30/03A.P. Pharma to Hold Third Quarter Conference Call November 7, 2003Printer Friendly Version
09/17/03A.P. Pharma Receives Additional Patent for 5-FU Microsponge Formulation; Patent Covering Carac Formulation Extended to 2021Printer Friendly Version
08/26/03A.P. Pharma Ready to Initiate Phase II Studies With APF112; Company Plans to Initiate Phase II Clinical Trials in SeptemberPrinter Friendly Version
08/04/03A.P. Pharma Reports Second Quarter Results; APF112 Phase II Clinical Package Submitted for FDA Review; Royalty Income Increases 11% Over 2Q 2002Printer Friendly Version
07/24/03A.P. Pharma to Hold Second Quarter Conference Call August 4, 2003Printer Friendly Version
05/05/03A.P. Pharma Reports First Quarter Results; Royalty Income Increases by 14% Over Q1 2002Printer Friendly Version
04/28/03A.P. Pharma to Hold First Quarter Conference Call May 5, 2003Printer Friendly Version
02/27/03A.P. Pharma Reports Fourth Quarter and Year-End 2002 ResultsPrinter Friendly Version
02/21/03A.P. Pharma to Hold Fourth Quarter Conference Call February 27, 2003Printer Friendly Version
02/14/03A.P. Pharma Sells Non-Core Business for Cash and RoyaltiesPrinter Friendly Version
12/11/02A.P. Pharma Names Robert L. Zerbe, M.D. To Board of Directors; New Member Brings To Board Additional Expertise in Regulatory Affairs and Clinical DevelopmentPrinter Friendly Version
12/03/02A.P. Pharma Establishes Timetable to Re-Initiate Clinical Program for APF112; Company provides regulatory update on progress towards Phase II clinical studiesPrinter Friendly Version
11/21/02A.P. Pharma Inc. CEO Michael O'Connell Talks to the Wall Street TranscriptPrinter Friendly Version
11/07/02A.P. Pharma Reports Third Quarter Financial Results; Third Quarter Royalty Income Increases 30%Printer Friendly Version
10/31/02A.P. Pharma to Hold Third Quarter Conference Call November 7, 2002Printer Friendly Version
08/16/02A.P. Pharma to Conduct Additional Preclinical Testing With APF112; Company Withdraws Proposed Phase II ProtocolPrinter Friendly Version
08/05/02A.P. Pharma Reports Second Quarter Financial Results; Royalty Income Continues to Increase; Clinical Programs Advance with Additional Corporate CollaboratorsPrinter Friendly Version
07/29/02A.P. Pharma to Hold Second Quarter Conference Call August 5, 2002Printer Friendly Version
05/15/02Second Formulation of RETIN-A MICRO Approved for U.S. Market; Launch Anticipated in June 2002; Potential to Significantly Increase A.P. Pharma's RoyaltiesPrinter Friendly Version
05/07/02A.P. Pharma Reports First Quarter Results; Clinical Program for APF112 Initiated in 2002; Royalty Income Up 39% Over First Quarter 2001Printer Friendly Version
05/01/02A.P. Pharma to Hold First Quarter Conference Call May 7, 2002Printer Friendly Version
03/05/02A.P. Pharma Reports Fourth Quarter and Year-End 2001 Results; Substantial Progress for the Biochronomer Drug Delivery System in 2001Printer Friendly Version
02/26/02A.P. Pharma To Hold Fourth Quarter Conference Call March 5, 2002Printer Friendly Version
01/29/02A.P. Pharma Reports Initiation of Clinical Program for APF112; First Clinical Study Fully EnrolledPrinter Friendly Version
12/20/01A.P. Pharma Files First Investigational New Drug Application for APF112 Formulation Using Biochronomer SystemPrinter Friendly Version
11/06/01A.P. Pharma Reports Third Quarter 2001 Results; Carac Achieves 26% Topical Market Share in Second Quarter after LaunchPrinter Friendly Version
10/31/01A.P. Pharma to Hold Third Quarter 2001 Conference Call Nov. 6, 2001Printer Friendly Version
09/26/01Second New Drug Application Filed for Retin-A Micro; Potential to Significantly Increase A.P. Pharma's RoyaltiesPrinter Friendly Version
08/07/01A.P. Pharma Reports Second Quarter 2001 Results; Royalty Income Increases, Proprietary Product-Development Programs UnderwayPrinter Friendly Version
07/23/01Retin-A Micro Receives Marketing Clearance in Canada; Johnson & Johnson Canada to Market Prescription Acne Treatment Containing Microsponge Systems in CanadaPrinter Friendly Version
06/26/01A.P. Pharma Successfully Completes Pre-Clinical Safety Evaluations Of Biochronomer™ SystemPrinter Friendly Version
06/01/01A.P. Pharma To Present At Wall Street Analyst Forum, June 7Printer Friendly Version
05/30/01A.P. Pharma Appoints Vice President Of Business DevelopmentPrinter Friendly Version
05/14/01Advanced Polymer Systems Changes Name To A.P. PharmaPrinter Friendly Version
05/03/01Advanced Polymer Systems Reports First Quarter 2001 ResultsPrinter Friendly Version
04/12/01Advanced Polymer Systems To Begin Receiving Royalties From Sales Of Dermik’s Carac™ For Treatment Of Actinic KeratosesPrinter Friendly Version
03/13/01Advanced Polymer Systems Reports Fourth Quarter And Full-Year 2000 ResultsPrinter Friendly Version
11/01/00Advanced Polymer Systems Appoints Experienced Pharmaceutical Industry Executive As ChairmanPrinter Friendly Version
10/30/00FDA Grants Marketing Clearance For New FormulationPrinter Friendly Version
08/02/00Advanced Polymer Systems Announces Key Management ChangesPrinter Friendly Version
07/26/00Advanced Polymer Systems Completes Sale Of Cosmeceutical Product Lines And Technology Rights For Certain Topical Pharmaceuticals To R.P. SchererPrinter Friendly Version